Details

Autor(en) / Beteiligte

• López-Ponce de León, Juan David
• Gómez-Mesa, Juan Esteban
• Saldarriaga, Clara
• Echeverría, Luis Eduardo
• Posada-Bastidas, Alejandro
• García, Juan Camilo
• Ochoa-Morón, Alejandro David
• Rolong, Balkis
• Manzur-Jatin, Fernando
• Mosquera-Jiménez, José Ignacio
• Pacheco-Jiménez, Oscar Alfredo
• Rodríguez-Cerón, Álvaro Hernán
• Rodríguez-Gómez, Patricia
• Rivera-Toquica, Fernando
• Rivera-Toquica, Alex

Titel

Prevalence, Clinical Characteristics, and Prognostic Impact of Kidney Disease on Heart Failure Patients: An Observational Study of the Colombian Heart Failure Registry

Ist Teil von

• Cardiorenal medicine, 2023-01, Vol.13 (1), p.292-300

Ort / Verlag

Basel, Switzerland

Erscheinungsjahr

2023

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Introduction: Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to increase this population’s risk of adverse outcomes. Nevertheless, evidence analyzing kidney dysfunction in HF is scarce in Latin American populations. We aimed to analyze the prevalence of kidney dysfunction and assess its association with mortality in patients diagnosed with HF enrolled in the Colombian Heart Failure Registry (RECOLFACA). Methods: RECOLFACA enrolled adult patients with HF diagnosis from 60 centers in Colombia during the period 2017–2019. The primary outcome was all-cause mortality. A Cox proportional-hazards regression model was used to assess the impact of the different categories of eGFR in mortality risk. A p value of <0.05 was considered significant. All statistical tests were two-tailed. Results: From the total 2,514 evaluated patients, 1,501 (59.7%) patients had moderate kidney dysfunction (eGFR <60 mL/min/1.73 m 2 ), while 221 (8.8%) patients were classified as having a severe kidney dysfunction (eGFR <30 mL/min/1.73 m 2 ). Patients with lower kidney function were most commonly males, had higher median age, and reported a higher prevalence of cardiovascular comorbidities. Moreover, different patterns of medications prescription were observed when comparing CKD versus non-CKD patients. Finally, eGFR <30 mL/min/1.73 m 2 was significantly associated with a higher mortality risk compared to eGFR >90 mL/min/1.73 m 2 status (HR: 1.87; 95% CI, 1.10–3.18), even after an extensive adjustment by relevant covariates. Conclusion: CKD represents a prevalent condition in the setting of HF. Patients with CKD and HF present with multiple sociodemographic, clinical, and laboratory differences compared with those only diagnosed with HF and present a significantly higher risk of mortality. A timely diagnosis and optimal treatment and follow-up of CKD in the setting of HF may improve the prognosis of these patients and prevent adverse outcomes.